Bicara Therapeutics files for a $200 million IPO

Bicara Therapeutics, a Phase I US biotech developing a bifunctional antibody to target solid tumors, on Thursday filed with the Securities and Exchange Commission (SEC) to raise up to $200 million in an initial public offering (IPO), according to Renaissance Capital.

Bicara Therapeutics' lead candidate, ficerafusp alfa (BCA101), is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR)-directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b).

Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-b signaling within the tumor microenvironment.